Do you want to read an article? Please log in or register.
Long-Term Efficacy and Safety of CT-P42 in Patients with Diabetic Macular Edema: 52-Week Results from a Phase 3 Randomized Clinical Trial
Macular Diseases
Related content
Macular Diseases
Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-related Macular Degeneration: A Phase 3 Randomized Trial
Ophthalmol Retina
Hamouz J, Nowosielska A, Święch-Zubilewicz A, Abengoechea S, Baumane K, Vajas A, Siewierska M, Veselovsky M, Veith M, Kerényi Á, Mange S, Baidya K, Laganovska G, Jürgens I, Papp A, Gosai J, Štefanickova J, Han M, Fryczkowski P, Zalewski D, Wang J, Wei W
doi: 10.1016/j.oret.2024.10.001
Macular Diseases
Intravitreal Aflibercept 8 mg in Neovascular Age-related Macular Degeneration: 96-Week Results from the Randomized Phase 3 PULSAR Trial
Ophthalmology
Korobelnik JF, Lanzetta P, Leal S, Holz FG, Clark WL, Eichenbaum D, Iida T, Sun X, Berliner AJ, Schulze A, Zhao M, Schmelter T, Schmidt-Ott U, Zhang X, Morgan-Warren P, Hasanbasic Z, Vitti R, Chu KW, Reed K, Bhore R, Cheng Y, Bai Z, Hirshberg B, Yancopoulos GD, Wong TY, PULSAR investigators
doi: 10.1016/j.ophtha.2025.08.022
Macular DiseasesRetinal Diseases
Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial
JAMA Ophthalmol
Pieramici DJ, Awh CC, Chang M, Emanuelli A, Holekamp NM, Hu AY, Suñer IJ, Wykoff CC, Brittain C, Howard D, Quezada-Ruiz C, Santhanakrishnan A, Latkany P
doi: 10.1001/jamaophthalmol.2025.0001
Macular Diseases
Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial
JAMA Ophthalmol
Khanani AM, Campochiaro PA, Graff JM, Marcus DM, Miller D, Mittra RA, Regillo C, Sheth VS, Bobbala A, Gune S, Lin S, Quezada-Ruiz C, Malhotra V
doi: 10.1001/jamaophthalmol.2025.0006
RECOMMENDED
Further Publications
Efficacy and Safety of Different Atropine Regimens for the Treatment of Myopia in Children: Three-Year Results of the MOSAIC Randomized Clinical Trial
★ 3
Recommended by
Prof. Dr Ke Yao, Faculty Member
JAMA Ophthalmol
Loughman J, Lingham G, Nkansah EK, Kobia-Acquah E, Flitcroft DI
doi: 10.1001/jamaophthalmol.2024.5703
Macular DiseasesRetinal Diseases
Faricimab Treat-and-Extend Dosing for Macular Edema due to Retinal Vein Occlusion: 72-Week Results From the BALATON and COMINO Trials
Ophthalmol Retina
Danzig CJ, Dinah C, Ghanchi F, Hattenbach LO, Khanani AM, Lai TYY, Shimura M, Abreu F, Arrisi P, Liu Y, Paris LP, Retiere AC, Willis JR, Schlottmann PG, BALATON and COMINO Investigators
doi: 10.1016/j.oret.2025.03.005
Glaucoma and Ocular Pressure
Long-term Safety and Performance of a Suprachoroidal Pressure Sensor System: Results of the EYEMATE-SC Trial Follow-Up Study
Ophthalmology
Micheletti E, Mansouri K, Dick HB, Hoffmann EM, Mackert MJ, Weinreb RN, Szurman P, EYEMATE-SC study group
doi: 10.1016/j.ophtha.2025.01.021
Retinal DiseasesFurther Publications
Efficacy and Safety of Mydriatic Microdrops for Retinopathy of Prematurity Screening: The MyMiROPS Randomized Clinical Trial
JAMA Ophthalmol
Seliniotaki AK, Lithoxopoulou M, Virgiliou C, Gika H, Dokoumetzidis A, Bougioukas KI, Raikos N, Diamanti E, Ziakas N, Haidich AB, Mataftsi A
doi: 10.1001/jamaophthalmol.2024.5462
Macular Diseases
Resolution of Angiographic Macular Leakage with Faricimab Versus Aflibercept in Patients with Diabetic Macular Edema in YOSEMITE/RHINE
Ophthalmol Retina
Goldberg RA, Mar FA, Csaky K, Amador M, Khanani AM, Gibson K, Kolomeyer AM, Sim DA, Murata T, Wang T, Udaondo P, Souverain A, Shildkrot YE, Vujosevic S, Nudleman E, Sivaprasad S
doi: 10.1016/j.oret.2024.11.015